{"id":2017,"date":"2024-04-11T13:47:17","date_gmt":"2024-04-11T13:47:17","guid":{"rendered":"https:\/\/stoxpo.com\/?p=2017"},"modified":"2024-04-11T13:47:18","modified_gmt":"2024-04-11T13:47:18","slug":"rallybio-collaborates-with-johnson-johnson-to-tackle-rare-disease-fnait","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2024\/04\/11\/rallybio-collaborates-with-johnson-johnson-to-tackle-rare-disease-fnait\/","title":{"rendered":"Rallybio Collaborates with Johnson & Johnson to Tackle Rare Disease FNAIT"},"content":{"rendered":"\n

Partnership Aims to Develop Therapeutic Solutions for Fetal and Neonatal Alloimmune Thrombocytopenia<\/h4>\n\n\n\n

Rallybio Corporation (RLYB) has announced a collaboration with Johnson & Johnson to advance therapeutic approaches for reducing the risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT). This collaboration includes a $6.6 million equity investment from Johnson & Johnson Innovation \u2013 JJDC, Inc.<\/p>\n\n\n\n

Rallybio’s focus lies in developing RLYB212, a human monoclonal anti-HPA-1a antibody designed to prevent pregnant individuals from alloimmunizing, thereby mitigating the risk of FNAIT in fetuses and newborns. With plans to initiate a Phase 2 dose confirmation study for RLYB212 in the second half of 2024, Rallybio aims to address the critical need for preventative treatment options in individuals at higher risk of FNAIT.<\/p>\n\n\n\n

The collaboration with Johnson & Johnson involves funding to raise awareness of Johnson & Johnson’s FNAIT clinical program alongside Rallybio’s ongoing natural history study. Together, the companies aspire to drive awareness, screening, and therapeutic advancements to combat FNAIT, ultimately improving outcomes for affected individuals.<\/p>\n\n\n\n

Read original press release:here<\/mark><\/a><\/p>\n\n\n\n

You might like this article:Vertex Pharmaceuticals to Acquire Alpine Immune Sciences in $4.9 Billion Deal<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Partnership Aims to Develop Therapeutic Solutions for Fetal and Neonatal Alloimmune Thrombocytopenia Rallybio Corporation (RLYB) has announced a collaboration with Johnson & Johnson to advance therapeutic approaches for reducing the risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT). This collaboration includes a $6.6 million equity investment from Johnson & Johnson Innovation \u2013 JJDC, Inc. Rallybio’s […]<\/p>\n","protected":false},"author":1,"featured_media":1430,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jnews-multi-image_gallery":[],"jnews_single_post":{"subtitle":"","format":"standard","video":"","gallery":"","source_name":"","source_url":"","via_name":"","via_url":"","override_template":"0","override":[{"template":"8","single_blog_custom":"","parallax":"1","fullscreen":"1","layout":"right-sidebar-narrow","sidebar":"author","second_sidebar":"single-right","sticky_sidebar":"1","share_position":"top","share_float_style":"share-monocrhome","show_share_counter":"0","show_view_counter":"0","show_featured":"1","show_post_meta":"1","show_post_author":"1","show_post_author_image":"1","show_post_date":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"1","post_reading_time_wpm":"300","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","show_prev_next_post":"1","show_popup_post":"1","number_popup_post":"1","show_author_box":"1","show_post_related":"1","show_inline_post_related":"0"}],"override_image_size":"0","image_override":[{"single_post_thumbnail_size":"crop-500","single_post_gallery_size":"crop-500"}],"trending_post":"0","trending_post_position":"meta","trending_post_label":"Trending","sponsored_post":"0","sponsored_post_label":"Sponsored by","sponsored_post_name":"","sponsored_post_url":"","sponsored_post_logo_enable":"0","sponsored_post_logo":"","sponsored_post_desc":"","disable_ad":"0"},"jnews_primary_category":{"id":"","hide":""},"jnews_social_meta":{"fb_title":"","fb_description":"","fb_image":"","twitter_title":"","twitter_description":"","twitter_image":""},"jnews_override_counter":{"override_view_counter":"0","view_counter_number":"0","override_share_counter":"0","share_counter_number":"0","override_like_counter":"0","like_counter_number":"0","override_dislike_counter":"0","dislike_counter_number":"0"},"jnews_post_split":{"enable_post_split":"0","post_split":[{"template":"1","tag":"h2","numbering":"asc","mode":"normal","first":"0","enable_toc":"0","toc_type":"normal"}]}},"categories":[308,359],"tags":[],"coauthors":[453],"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/2017"}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=2017"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/2017\/revisions"}],"predecessor-version":[{"id":2018,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/2017\/revisions\/2018"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1430"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=2017"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=2017"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=2017"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=2017"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}